Yantai Dongcheng Biochemicals (002675.SZ) has released its performance for 2024, with a net profit of 184 million yuan, a decrease of 12.35%.

Yantai Dongcheng Biochemicals (002675.SZ) released its annual report for the year 2024, during the reporting period, the company achieved operating income of 2.869 billion yuan, a decrease of 12.42% year-on-year. Net profit attributable to shareholders of the listed company was 184 million yuan, a decrease of 12.35% year-on-year. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 79.274 million yuan, a decrease of 62.69% year-on-year. Basic earnings per share were 0.2229 yuan. It is proposed to distribute a cash dividend of 0.3 yuan (including tax) per 10 shares to all shareholders. During the reporting period, the sales revenue of the nuclear medicine business segment was 1.012 billion yuan, a decrease of 0.52% year-on-year. Among them, the key product 18F-FDG achieved operating income of 4.21 billion yuan, an increase of 0.25% year-on-year; Yunke injection achieved operating income of 2.31 billion yuan, a decrease of 5.48% year-on-year; Technetium-labeled drugs achieved operating income of 0.99 billion yuan, a decrease of 0.99% year-on-year. The sales revenue of the API business segment was 1.255 billion yuan, a decrease of 25.17% year-on-year. Among them, the key product heparin API products achieved operating income of 8.44 billion yuan, a decrease of 36.32% year-on-year. The decrease in sales revenue of heparin products was mainly due to the decrease in the selling price of heparin sodium. The sales revenue of the formulation business segment was 0.325 billion yuan, a decrease of 18.66% year-on-year; the key product Naqu injection achieved sales revenue of 1.28 billion yuan, an increase of 74.86% year-on-year, mainly due to the product entering the national centralized procurement and increasing sales volume due to policy factors.